We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content

Advertisement

SpringerLink
Log in

Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender

Results from the PROBE-HF study

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

The association between natriuretic peptides and clinical outcome in asymptomatic hypertensive and diabetic patients with no clinical evidence of heart failure (HF) is still unclear. We assessed the prognostic value of NT-pro BNP, and its interactions with age and gender, in a cohort of asymptomatic, stage A/B HF hypertensive and diabetic patients enrolled in primary care.

Methods

NT-proBNP was measured in 1012 asymptomatic subjects with systemic hypertension and/or type-2 diabetes (age 66.6 ± 7.8 years, 48 % males) with no clinical evidence of HF. Patients were prospectively followed over 49.8 ± 6.7 months for the development of cardiac death, HF hospitalization, and nonfatal myocardial infarction.

Results

Patients with NT-proBNP above the 80th age- and gender-specific percentile showed a threefold risk of events as compared to those with NT-proBNP under this cut-off [hazard ratio 3.2 (2.6–8.3), p < 0.0001]. In multivariable analysis, NT-proBNP added independent and incremental prognostic information to a predictive model including established risk factors (p < 0.0001). After stratification by age, increased NT-proBNP predicted outcome among patients in the second and third age tertiles, but not among those in the first tertile. Increased NT-proBNP was associated with a 3.6-fold risk in women and a 2.9-fold risk in men. Addition of the gender-NT-proBNP interaction to prognostic models further improved prediction of events (p = 0.014).

Conclusions

NT-proBNP measurement adds independent and incremental information for the prediction of clinical outcome in asymptomatic, stage A-B HF hypertensive and diabetic patients taken from primary care. This prognostic value might be further evident in the elderly and among women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. Schneider HG, Lam L, Lokuge A et al (2009) B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med 150:365–371

    Article  PubMed  Google Scholar 

  2. Rosenberg J, Schou M, Gustafsson F, Badskjaer J, Hildebrandt P (2009) Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J 30:66–73

    Article  PubMed  Google Scholar 

  3. Frankenstein L, Remppis A, Nelles M et al (2008) Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J 29:2634–2640

    Article  CAS  PubMed  Google Scholar 

  4. Vazquez R, Bayes-Genis A, Cygankiewicz I, MUSIC Investigators et al (2009) The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 30:1088–1096

  5. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663

  6. Leistner DM, Klotsche J, Pieper L et al (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 102:259–268

    Article  PubMed  Google Scholar 

  7. Linssen GC, Bakker SJ, Voors AA et al (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31:120–127

    Article  CAS  PubMed  Google Scholar 

  8. Kara K, Mahabadi AA, Geisel MH et al (2014) B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events–the Heinz Nixdorf recall study. Clin Res Cardiol 103:125–132

    Article  CAS  PubMed  Google Scholar 

  9. Klaar U, Gabriel H, Bergler-Klein J et al (2011) Prognostic value of serial B-type natriuretic peptide measurement in asymptomatic organic mitral regurgitation. Eur J Heart Fail 13:163–169

    Article  CAS  PubMed  Google Scholar 

  10. Daniels LB, Clopton P, Jiang K, Greenberg B, Maisel AS (2010) Prognosis of stage A or B heart failure patients with elevated B-type natriuretic peptide levels. J Card Fail 16:93–98

    Article  PubMed  Google Scholar 

  11. Huelsmann M, Neuhold S, Strunk G et al (2008) NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 29:2259–2264

    Article  CAS  PubMed  Google Scholar 

  12. Pedersen F, Raymond I, Kistorp C, Sandgaard N, Jacobsen P, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide in arterial hypertension: a valuable prognostic marker of cardiovascular events. J Card Fail 11:S70–S75

    Article  CAS  PubMed  Google Scholar 

  13. Loke I, Squire IB, Davies JE, Ng LL (2003) Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 5:599–606

    Article  CAS  PubMed  Google Scholar 

  14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982

    Article  CAS  PubMed  Google Scholar 

  15. Betti I, Castelli G, Barchielli A et al (2009) The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure.The PROBE-HF study. J Card Fail 15:377–384

    Article  CAS  PubMed  Google Scholar 

  16. Yancy CW, Jessup M, Bozkurt B et al (2013) ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 128:e240–e327

    Article  PubMed  Google Scholar 

  17. Mancia G, Fagard R, Narkiewicz K et al (2013) ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J 34:2159–2219

    Article  PubMed  Google Scholar 

  18. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. World Health Org, Geneva

  19. Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 16:233–270

    Article  PubMed  Google Scholar 

  20. Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 18:1440–1463

    Article  PubMed  Google Scholar 

  21. Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165–193

    Article  PubMed  Google Scholar 

  22. Vahanian A, Baumgartner H, Bax J et al (2007) The task force on the management of valvular heart disease of the European society of cardiology. Eur Heart J 28:230–268

    PubMed  Google Scholar 

  23. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R (2004) Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 6:365–368

    Article  CAS  PubMed  Google Scholar 

  24. McKie PM, Cataliotti A, Lahr BD et al (2010) The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol 55:2140–2147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616

    Article  CAS  PubMed  Google Scholar 

  26. Onodera M, Nakamura M, Tanaka F et al (2012) Plasma B-type natriuretic peptide is useful for cardiovascular risk assessment in community-based diabetes subjects: comparison with albuminuria. Int Heart J 53:176–181

    Article  CAS  PubMed  Google Scholar 

  27. Januzzi JL, van Kimmenade R, Lainchbury J et al (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27:330–337

    Article  CAS  PubMed  Google Scholar 

  28. Rodeheffer RJ, Jacobsen SJ, Gersh BJ et al (1993) The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 68:1143e50

  29. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D (1993) Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88:107e15

  30. Dini FL, Whalley G, Poppe K et al (2009) Plasma N-terminal protype-B natriuretic peptide and restrictive mitral flow to risk-stratify patients with stage B heart failure. Clin Cardiol 32:711–717

    Article  PubMed  Google Scholar 

  31. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA (2008) Biomarkers to predict recurrent cardiovascular disease: the heart and soul study. Am J Med 121:50–57

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA (2007) N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297:169–176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Fradley MG, Larson MG, Cheng S et al (2011) Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham heart study). Am J Cardiol 108:1341–1345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gustafsson F, Steensgaard-Hansen F, Badskjær J, Poulsen AH, Corell P, Hildebrandt P (2005) Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 11:S15–S20

    Article  CAS  PubMed  Google Scholar 

  35. Hildebrandt P, Collinson PO, Doughty RN et al (2010) Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 31:1881–1889

    Article  CAS  PubMed  Google Scholar 

  36. Nielsen OW, Kirk V, Bay M, Boesgaard S, Nielsen H (2004) Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital heart failure study (CHHF). Eur J Heart Fail 6:275–279

    Article  PubMed  Google Scholar 

  37. Frankenstein L, Clark AL, Goode K et al (2009) The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age. Heart 95:825–829

    Article  CAS  PubMed  Google Scholar 

  38. Olsen MH, Hansen TW, Christensen MK et al (2008) Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens 26:26–34

    Article  CAS  PubMed  Google Scholar 

  39. Franke J, Lindmark A, Hochadel M et al (2015) Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the heart failure survival score. Clin Res Cardiol 104:334–341

    Article  PubMed  Google Scholar 

  40. Kara K, Lehmann N, Neumann T et al (2015) NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf recall study. Int J Cardiol 183:155–161

    Article  PubMed  Google Scholar 

  41. Christ M, Laule-Kilian K, Hochholzer W et al (2006) Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 48:1808–1812

    Article  CAS  PubMed  Google Scholar 

  42. Nakamura M, Tanaka F, Onoda T et al (2010) Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. Int J Cardiol 143:124–129

    Article  PubMed  Google Scholar 

  43. Schroten NF, Damman K, Valente MA et al (2015) Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clin Res Cardiol. doi:10.1007/s00392-015-0881-9

    PubMed  PubMed Central  Google Scholar 

  44. Ogah OS, Davison BA, Sliwa K et al (2015) Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: results of the THESUS-HF study. Clin Res Cardiol 104:481–490

    Article  PubMed  Google Scholar 

  45. Meyer S, Brouwers FP, Voors AA et al (2015) Sex differences in new-onset heart failure. Clin Res Cardiol 104:342–350

    Article  PubMed  Google Scholar 

  46. Ballo P, Betti I, Barchielli A et al (2013) Body mass index, gender, and clinical outcome among hypertensive and diabetic patients with stage A/B heart failure. Obesity 21:E500–E507

    PubMed  Google Scholar 

  47. Schocken DD, Benjamin EJ, Fonarow GC et al (2008) Prevention of heart failure: a scientific statement from the American heart association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group. Circulation 117:2544e65

  48. Daugherty SL, Masoudi FA, Ellis JL et al (2011) Age-dependent gender differences in hypertension management. J Hypertens 29:1005–1011

  49. Homko CJ, Zamora L, Santamore WP, Kashem A, McConnell T, Bove AA (2010) Gender differences in cardiovascular risk factors and risk perception among individuals with diabetes. Diabetes Educ 36:483–488

    Article  PubMed  Google Scholar 

  50. Scirica BM, Morrow DA, Bode C et al (2010) Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 31:1993–2005

    Article  CAS  PubMed  Google Scholar 

  51. Staub D, Nusbaumer C, Zellweger MJ et al (2006) Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J 151:1223–1230

    Article  CAS  PubMed  Google Scholar 

  52. Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P (2009) N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 26:872–879

    Article  CAS  PubMed  Google Scholar 

  53. Poulsen MK, Henriksen JE, Vach W et al (2010) Identification of asymptomatic type 2 diabetes mellitus patients with a low, intermediate and high risk of ischaemic heart disease: is there an algorithm? Diabetologia 53:659–667

    Article  CAS  PubMed  Google Scholar 

  54. Singh HS, Bibbins-Domingo K, Ali S, Wu AH, Schiller NB, Whooley MA (2009) N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. Clin Cardiol 32:447–453

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wiersma JJ, van der Zee PM, van Straalen JP et al (2009) NT-pro-BNP is associated with inducible myocardial ischemia in mildly symptomatic type 2 diabetic patients. Int J Cardiol 145:295–296

    Article  PubMed  Google Scholar 

  56. Kováts T, Wettstein A, Nagy E, Tomcsányi J (2008) Bradycardia can induce increased serum natriuretic peptide-level. Int J Cardiol 123:e43–e44

    Article  PubMed  Google Scholar 

  57. Baggish AL, van Kimmenade RR, Januzzi JL Jr (2008) The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol 101:43–48

    Article  PubMed  Google Scholar 

  58. Kováts T, Tomcsányi J (2009) Bradycardia and B-type natriuretic peptide. Int J Cardiol 145:238–239

    Article  Google Scholar 

  59. Sinning C, Kieback A, Wild PS et al (2014) Association of multiple biomarkers and classical risk factors with early carotid atherosclerosis: results from the Gutenberg Health Study. Clin Res Cardiol 103:477–485

    Article  CAS  PubMed  Google Scholar 

  60. Takeishi Y (2014) Biomarkers in heart failure. Int Heart J 55:474–481

    Article  CAS  PubMed  Google Scholar 

  61. Friões F, Lourenço P, Laszczynska O et al (2015) Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol 104:491–499

    Article  PubMed  Google Scholar 

  62. Bayes-Genis A, Ordonez-Llanos J (2015) Multiple biomarker strategies for risk stratification in heart failure. Clin Chim Acta 443:120–125

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Roche Diagnostic, Milan, Italy.

Author information

Authors and Affiliations

  1. Department of Cardiology, S. Maria Annunziata Hospital, Via dell’antella 58, Florence, Italy

    Piercarlo Ballo & Irene Betti

  2. Institute for Oncological Studies and Prevention, Florence, Italy

    Alessandro Barchielli

  3. Epidemiology Unit, Local Health Authority, Florence, Italy

    Daniela Balzi

  4. Department of Cardiology, Careggi Hospital, Florence, Italy

    Gabriele Castelli

  5. Division of Cardiology, Department of Cardiovascular Sciences, European Hospital, Rome, Italy

    Leonardo De Luca

  6. Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Mihai Gheorghiade

  7. Regional Health Agency, Local Health Authority, Florence, Italy

    Alfredo Zuppiroli

Authors
  1. Piercarlo Ballo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irene Betti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Barchielli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniela Balzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gabriele Castelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leonardo De Luca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mihai Gheorghiade
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alfredo Zuppiroli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Piercarlo Ballo.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest in connection with this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ballo, P., Betti, I., Barchielli, A. et al. Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender. Clin Res Cardiol 105, 421–431 (2016). https://doi.org/10.1007/s00392-015-0937-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-015-0937-x

Keywords

Search

Navigation